A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group
Publication in refereed journal


Times Cited
Web of Science18WOS source URL (as at 16/11/2020) Click here for the latest count
Altmetrics Information
.

Other information
AbstractPurpose Fenretinide is a synthetic retinoid with activity in prostate cancer and other cell lines. The aim of this study was to assess the efficacy and tolerability of fenretinide in chemotherapy-na < ve men with hormone refractory prostate cancer.
All Author(s) ListMoore MM, Stockler M, Lim R, Mok TSK, Millward M, Boyer MJ
Journal nameCancer Chemotherapy and Pharmacology
Year2010
Month10
Day1
Volume Number66
Issue Number5
PublisherSPRINGER
Pages845 - 850
ISSN0344-5704
eISSN1432-0843
LanguagesEnglish-United Kingdom
KeywordsFenretinide; Hormone refractory; Prostate cancer
Web of Science Subject CategoriesOncology; ONCOLOGY; Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY

Last updated on 2020-17-11 at 00:21